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In discussing the state of insulin
in the blood, I should like to review
briefly the regulation of insulin
secretion and what is known about
its manner of synthesis and release.
Since some of the insulin in the
blood may be in an ineffective or
inactive state, I shall refer to active
insulin as efjective insulin.
METABOLITE STIMULATORS

The stimulus acting on the pancreas that controls the level of
effective insulin in the blood is
probably related to more than one
metabolite. For many years glucose
was considered the only substance
capable of insulin stimulation, but
recently it has been shown that
keto-acids (Mebane and Madison,
1962) and certain amino acids such
as leucine and arginine (Floyd et
al., 1965; Merimee et al., 1965)
can also stimulate insulin release.
There is need to learn whether this
has physiological significance before assigning it a specific role in
the checks and balances of human
metabolism. Intravenous studies
using arginine will be followed by
oral feedings of appropriate animal
proteins to determine whether or
not there will be an increase in the
level of serum insulin without a
rise in blood sugar.

* The schema presented here is the
result of much discussion involving
all members of the endocrine division
at the Johns Hopkins Hospital. Dr.
Kenneth Zierler, Dr. David Rabinowitz, .and Dr. Thomas Merimee are
especially cited in the formulation of
· these concepts.
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SENSING-RELEASING
MECHANISMS

The manner in which glucose or
other metabolites bring about the
secretion of insulin is unknown. It
is reasonable to postulate that a
sensing device must be present that
recognizes the amount of the specific stimulator present and informs the pancreas that insulin is
needed. This immediately raises the
possibility that a pathologic state
could exist wherein a faulty sensing
device would fail to inform the
pancreas of the need, and insulin
would not be secreted despite the
presence of normal quantities of
insulin in the pancreas. Studies with
the sulfonylurea drugs may perhaps be interpreted as bearing on
this question. It is clear that insulin
can exist within the islet cells quite
unaware of the hyperglycemic blood
flowing past and that sulfonylurea
drugs can bring about the release
of this insulin. These drugs may
activate a sensing device. It is
equally possible that they may activate a releasing mechanism for
we cannot separate these two postulated functions clinically. In individuals with adequate pancreatic
stores of insulin that are not responsive to elevated levels of glucose, the sulfonylurea drugs bring
about a more normal response to
the stimuli. There is increasing evidence that there is carbohydrate
intolerance that advances with age
(Andres, 1966, in press) and again
it seems likely that this relative insensitivity comes about through a
failure either of the sensing device
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or releasing mechanism. Perhaps
other conditions which alter insulin
release, such as the glucose intolerance following fasting, may relate
to these mechanisms.
SYNTHESIS AND STORAGE

Although we can say little about
the mechanisms of release of insulin, we are indebted to the beautiful studies by Lacy ( 1961) with
the electron microscope for an exposition of the migration of the
insulin granule across the beta-cell
to the cell surface. On reaching the
cell surface, the envelope of the
beta granule appears to coalesce
with the surface membrane where
upon the beta granule is discharged
into the extracellular space. At this
point, unfortunately, the resolution
of the electron microscope does
not allow further physical view of
the discharged granule. After discharge of the previously stored
insulin, empty sacks are again seen
in the beta cell; these are frequently surrounded in part by a
protein believed to be ribonuclear
protein. The ribonuclear protein
granules clustered about the sack
slowly disappear as the amorphous
material fills the empty sack, and
it is easy to presume that we have
witnessed the synthesis of insulin
on a template. The amorphous material in the sack is next seen to
condense into a storage form that
is typical of the beta granules previously discharged. The discharge
of these granules in response to
known stimuli such as glucose and
sulfonylurea drugs adds further to
the circumstantial evidence that we
are in fact witnessing the synthesis
and release of insulin.
Randle and his associates (see
Coore and Randle, 1964) have
been able to show that insulin can
be released from pancreatic slices
in vitro by the addition of glucose
to the medium. In this system,
epinephrine inhibits the release of
insulin by both glucose and the sulfonylureas. Perhaps the most important observation has been that

he has been able to prevent the release of insulin from the pancreas
by the addition of manoheptulose
when glucose is added to the medium, but manoheptulose does not
prevent the release of insulin under
the stimulus of the sulfonylureas.
This is the first time that anyone
has been able to separate the release mechanisms associated with
glucose from those related to the
sulfonylureas and parenthetically
this suggests that the release mechanism rather than the sensing device
is the site of action of the sulfonylureas in human subjects.
CIRCULATING INSULIN

In considering the state of insulin in the blood, we must deal
with certain direct questions: What
is its form? How is it transported?
And what is the material being
measured which we call "insulin?"
These are fundamental questions,
but our answers must be incomplete.
From the work of Sanger (1960)
we have the precise structure of the
insulin molecule, and the molecular
weight is known to be approximately 6,000. It has not been possible to be certain of the form
taken by circulating insulin. It
probably circulates as a double
molecule or dimer with a molecular weight of 12,000, but it may
circulate in aggregates of three or
four molecules (Prout, 1963).
There is some evidence that the
insulin may be transported in the
blood attached to a carrier protein,
but this cannot be definitely proven
at this time.
Insulin is measured in biologic
fluids on the basis of its biologic
effect or its immunologic properties.
In general, there are two types of
biological assay, one measuring the
effect of glucose uptake or glycogen
deposition in a rat hemi-diaphragm
and the other measuring the incorporation of C" from labelled glucose into glycogen or CO. by the
rat epididymal fat pad. Both of
these tests measure a net biologi-

cal effect which may be altered as
a result of several modifying factors either potentiators or inhibitors. For this reason, the activity
thus measured is referred to as the
"insulin-like activity"' or ILA. The
immunoassay of Berson and Yalow
( 1960) identifies immunologically
active insulin quite specifically and
with considerable sensitivity; it is,
of course, able to tell us nothing
about the biological activity of the
thing that is measured. About these
two types of assay have grown up
two schools of thought which divide the investigators interested in
this field .
Faced with this dilemma, it is of
some comfort to consider the number of ways in which the ILA as
measured by the diaphragm and the
immunoassay give parallel results
(table 1). By both tests the blood
insulin is low in the fasting subjects but rises after glucose or after
administration of the sulfonylureas.
By both tests the blood insulin is
high in patients with insulin secreting islet cell tumors. In obese patients both assay techniques reveal
increased insulin levels. The levels
may be high by both assay methods in certain adult diabetes, and
most importantly immunologically
active insulin and ILA as tested by
the rat hemi-diaphragms are both

TABLE l
Similarities in the Assay of Insulin in Whole

Serum by the Rat Diaphragm and by the
Immunoassay

.

l) Law insulin levels in blood of fasting patients
2) Rise of insulin after glucose administration
3) Rise of insulin after sulfonylurea administration

4) High levels of insulin In hyperinsulinlsm
5) Elevated levels of Insulin in some obese
subjects
6) Suppre~lon of Insulin in vitro and in

vivo by specific Insulin antibodies
7) Disappearance of Insulin ofter pancreatec.tomy

8) Absence of Insulin in serum of patients

in diabetic keto-acidosis
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suppressed by anti-insulin antibodies either in vitro or in vivo.
Finally, the insulin measured by
either method disappears when the
pancreas has been removed. In
these respects both assays would
appear to be measuring the same
material.
The observation that insulin-like
activity measured by the fat pad
was several fold that measured
by the diaphragm or the immunoassay turned attention to the question of whether or not a circulating
form of insulin existed which had
lost, or perhaps had never had,
immunologic identity. By means of
a cation exchange resin column,
Antoniades and his associates
( 1964) separated a form of insulinlike activity that could be measured
initially by the fat pad but not by
the diaphragm or immunoassay.
This was called "bound" insulin as
opposed to the "free" form. Others
have found insulin-like activity that
is "atypical" (Samaan et al., 1963)
or "non-suppressible" (Froesch et
al., 1963) because the activity unlike that of crystalline insulin is
not inhibited by anti-insulin antisera added to the test medium. 'Ve
can conveniently consider together
these various types of "bound,"
"complexed," "non-suppressible,"
or "typical" insulins and contrast
them to insulin that is measurable
by the other methods (table 2).
One difficult problem confronting the proponents of atypical insulin in that some "atypical" insulin
seems to persist in the blood for
considerable periods of time after
pancreatectomy (Goldberg and
Egdahl, 1961). Before attempting
to give clinical relevance to ILA
of the "atypical" type, a second
observation requires physiologic
explanation. We are asked, for
example, to believe that ILA measured only by the fat pad is circulating in excess quantities in patients
with decompensated diabetes in
whom the principle evidence of
decompensation is failure of insulin
to act normally upon fat synthesis
(Steinke et al., 1961). These criti16

TABLE 2
Differences Between "Typical" and "Atypical" insulin
"Atypical"

"Typical"
Measured by diaphragm
fat-pad and immunoassay

Assay

Inhibited

Effect of
antiserum

Measured by fat-pad

Not inhibited

Disappears

Remains

Origin

Pancreas

Unknown

Keto-aci dos is

Absent

Effect of pancreatectomy

Other unresolved
questions

Present in large
quantity

Biologic activity of insulin measured immunologically is not known

Cannot be converted
reproducibly to
typical form

TABLE 3
The Feed-back Mechanism of Insulin Synthesis and Release
Metabolite
stimulator

l

Cellular response
Metabolite utilization

t

Sensing-releasing
device

Insulin-cell receptor
linkage

Pancreatic synthesis
and storage

Insulin in biologic
fluids

t
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cisms have lead many to deny that
"atypical" insulin has any real relationship to true pancreatic insulin.
Despite these difficulties, it is theoretically possible that some form
of insulin may exist which is different from the insulin measured immunologically and by its biologic
effects on muscle and further study
of the problem will be necessary.
A FEED-BACK MECHANISM

We can now picture the glucose
insulin regulating mechanism as a
feed-back system (table 3). A metabolic stimulator, usually glucose,
is measured by a sensing device
which tells the pancreatic cell to
release and re-synthesize insulin in
relation to metabolic need. After
circulating insulin has arrived in the
blood, it is picked up by a specific
cell receptor and initiates a cellular
response. The cellular response not
only serves a metabolic need but
also removes from the blood some
of the metabolic stimulator that
initiated the cycle. As a result of
the fall in the metabolite, no further stimulation for insulin release
is given, and the feed-back mechanism is satisfied. Various other factors can presumably inhibit or potentiate the different steps of this
process.
In this framework the diabetes
with which we have been most
familiar in the past is associated
with failure of insulin release from
the pancreas. This is most typically
exemplified as the pancreatic exhaustion of juvenile diabetes. It is
also true of the pancreas that has
been destroyed by pancreatitis,
hemochromatosis, or removed by
the surgeon's knife. It may be seen
where pancreatic exhaustion results
from metabolic stresses such as
hyperthyroidism, multiple pregnancies, or long-standing obesity. In all
cases the pancreas is no longer able
to respond to demand, and clinical
diabetes is seen. In true pancreatic
exhaustion the sulfonylureas are, of
course, ineffective.
We should also note that a state

of functional low insulin output
exists where there is either dulling
of the sensing device or interference with insulin release; either
of these mechanisms impairs the
ability of the pancreas to deliver
insulin on demand. In these instances, the sulfonylureas release
insulin. Epinephrines and the thiazides inhibit release of insulin.
The new concept that must be
brought into this scheme is the
clinical situation in which metabolic
abnormalities of the type seen in
diabetes are present in spite of
high circulating levels of insulin.
A state of impaired carbohydrate
intolerance in association with a
high level of plasma insulin can be
understood if the insulin present
is ineffective. It is also possible to
recognize the clinical syndrome in
which normal high levels of insulin
compete with antagonists such as
growth hormone, acromegaly, or
adrenal steroids. A similar though
less well defined impairment of insulin is seen in association with
obesity. Here again we may see
impaired carbohydrate tolerance in
the presence of high circulating
levels of insulin (Karam et al.,
1963). In this state it appears
likely that the impairment to insulin function is located primarily
at the level of cellular response.
The same may be true in carbohydrate induced hypertriglyceridemia, a condition closely allied to
diabetes but not necessarily true
diabetes. There is some evidence
that the lipoatrophic form of diabetes may be characterized by high
levels of circulating insulin that are
rendered ineffective by an insulin
antagonist (Louis et al., 1965).
"Prediabetes" may take one of
two forms. It may be a state in
which high levels of insulin are put
out to overcome peripheral impairment or circulating antagonists but
in which carbohydrate intolerance
cannot be demonstrated by ordinary techniques. This state is readily
understood within the present
framework. "Prediabetes" may also
be present in a patient who shows
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evidence of the "complications" of
diabetes before carbohydrate tolerance is lost. There is some evidence
that different tissues react to different levels of insulin and by presumption that levels of insulin adequate for the metabolism of some
tissue would be ineffective for
others. This may well be the reason why it is possible to see degenerative complications in the
retina that is typical of diabetic
retinopathy in some patients who
have no carbohydrate intolerance.
The same may be true of patients
who develop vascular disease in
the absence of alterations in carbohydrate utilization. Perhaps the
future study will allow us to demonstrate that tissue sensitivity in
such patients is the cause of the
degenerative complications. There
is abundant evidence that complications may be seen in the absence
of carbohydrate impairment, and
we can no longer accept the frequently stated belief that control of
carbohydrate metabolism in diabetes will prevent all other forms
of the "complications."
Much of the theme presented
here can be verified, but much of
it still remains speculative. It is
probably possible to place all variants of the diabetic state somewhere within this cycle so that diabetes will eventually become better
understood as a complex metabolic
disorder involving all tissues and
all metabolites rather than the
simple derangement of carbohydrate utilization.

SUMMARY

Diabetes mellitus has been reviewed as a group of conditions
with impaired function of one or
more portions of a feed-back system involving the release and utilization of insulin. It is hoped that
this may form a useful scheme by
which we can study and understand
a number of complex metabolic
states which we must still collectively refer to as diabetes mellitus.
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